All In MedTech

FDA Clearance Tracker · P960007

TRANSCYTE HUMAN FIBROBLAST-DERIVED TEMPORARY SKIN SUBSTITUTE

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Mar 18, 1997 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Mar 18, 1997

Approved (conversion)

Time to decision

354 days

Received Mar 29, 1996. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P960007
Device name
TRANSCYTE HUMAN FIBROBLAST-DERIVED TEMPORARY SKIN SUBSTITUTE
Applicant location
San Diego, CA
Received
Mar 29, 1996
Decided
Mar 18, 1997
Decision
Approved (conversion)
Supplements
19 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code MGR

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE DERMAGRAFT-TC(TM). THE DEVICE IS INDICATED FOR USE AS A TEMPORARY WOUND COVERING FOR SURGICALLY EXCISED FULL-THICKNESS AND DEEP PARTIAL-THICKNESS THERMAL BURN WOUNDS IN PATIENTS WHO REQUIRE SUCH A COVERING PRIOR TO AUTOGRAFT PLACEMENT

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code MGR. The earliest in FDA's data is P900033, decided Mar 1, 1996.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Shire Regenerative Medicine

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.